Cantor Fitzgerald Estimates Alumis FY2026 Earnings

Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Alumis in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the company will earn ($2.60) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share.

Other research analysts have also recently issued research reports about the company. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of Alumis in a research note on Wednesday, April 30th. Oppenheimer lowered their price objective on Alumis from $26.00 to $25.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Finally, Guggenheim assumed coverage on shares of Alumis in a research report on Tuesday. They issued a "buy" rating and a $18.00 target price on the stock. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $22.86.

Alumis Stock Performance

Alumis stock traded down $0.07 during trading hours on Tuesday, hitting $3.36. 811,827 shares of the stock traded hands, compared to its average volume of 397,675. Alumis has a one year low of $3.18 and a one year high of $13.53. The firm's 50-day moving average price is $5.16 and its two-hundred day moving average price is $6.19.

Alumis (NASDAQ:ALMS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.35).

Institutional Trading of Alumis

Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its stake in shares of Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock worth $102,000 after purchasing an additional 2,949 shares during the last quarter. Jane Street Group LLC bought a new stake in Alumis in the 1st quarter worth about $111,000. Goldman Sachs Group Inc. raised its position in Alumis by 24.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company's stock worth $378,000 after buying an additional 11,949 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock valued at $77,000 after acquiring an additional 4,926 shares during the period. Finally, Corebridge Financial Inc. lifted its stake in Alumis by 53.0% during the 1st quarter. Corebridge Financial Inc. now owns 10,658 shares of the company's stock valued at $65,000 after acquiring an additional 3,693 shares during the period.

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju purchased 159,920 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were purchased at an average price of $4.55 per share, for a total transaction of $727,636.00. Following the completion of the acquisition, the director now directly owns 3,426,418 shares in the company, valued at $15,590,201.90. This represents a 4.90% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Foresite Labs, Llc acquired 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was purchased at an average price of $4.34 per share, with a total value of $86,800.00. Following the completion of the acquisition, the insider now owns 4,247,670 shares in the company, valued at $18,434,887.80. The trade was a 0.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 397,044 shares of company stock valued at $1,891,895.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.